Refine Results
Sort By
From
To
Page 1
Page 1
Management of atopic dermatitis : Methods and challenges
This new edition builds upon the foundational knowledge covered in the first edition, covering the epidemiology, pathogenesis, and clinical presentation of atopic dermatitis in both pediatric and adult patients. It provides an overview of the mechanism and presentation of atopic dermatitis and focuses on the management methods experienced dermatologists have used to successfully manage atopic dermatitis. The book includes new chapters describing the special considerations for atopic dermatitis in skin of color patients, dedicated chapters on topical and oral prescription management reflected the latest FDA-approved treatments, and also a chapter covering the updated guidelines from the American Academy of Dermatology. A final chapter includes updates on the future of atopic dermatitis treatment.
Macular Degeneration
Macular Degeneration: Science and Medicine in Practice provides a unique overview of current thinking in the pathogenesis, incidence and treatment of AMD. It includes, for the first time, a synthesis of the views of the world's leading scientists and practitioners regarding retinal biology, basic mechanisms, clinical and pathogenetic processes, and rational approaches to intervention.
Machine learning for neurodegenerative disorders : advancements and applications
Explores the application of machine learning to the understanding, early diagnosis, and management of neurodegenerative disorders. With a specific focus on its role in ongoing clinical trials, the book covers essential topics such as data collection, pre-processing, feature extraction, model development, and validation techniques. It delves into the applications of neuroimaging techniques like magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) in the diagnosis and understanding of neurodegenerative disorders. Additionally, the book examines various machine-learning algorithms employed for biomarker discovery in neurodegenerative disorders. It highlights the role of neuroinformatics and big data analysis in advancing the understanding and management of neurodegenerative disorders. Furthermore, the book reviews future prospects and presents the ethical considerations and regulatory challenges associated with implementing machine learning approaches in the diagnosis, treatment, and prevention of neurodegenerative disorders.
Leptomeningeal Metastases
Leptomeningeal Metastases provides the reader with an overview of the state-of-the-art therapy for the leptomeningeal patient with additional information on epidemiology, symptom management, new clinical trials, and current basic research in animal models for experimental therapies. "Leptomeningeal metastases remains a devastating manifestation of hematologic malignancies and solid tumors. Leading figures in the field review the pathophysiology and clinical consequences of this process. State-of-the-art treatment strategies are presented highlighting advances in current management."
Key Clinical Trials in Erectile Dysfunction
Represents a critical appraisal of the major clinical trials that have had a significant impact on clinical research and practice during the last decade. Each trial follows a strict format, starting with reference to the original source of publication, details on the key investigators and their methods of research. The strengths and weaknesses of each trial are discussed as well as their influence on clinical practice. Articles are complemented by a diagrammatic summary of the trial design and the key findings.
Cerebral Hemorrhage
Cerebral hemorrhage is a common and often fatal subtype of stroke. while in the past it has received relatively little attention compared to ischemic stroke, there have been major advances in our understanding of this devastating form of stroke. The papers by world experts cover the field from molecular biology to clinical trials.
Cancer in adolescents and young adults
The chapters highlight the initial efforts of this Committee in addressing the scope of the problem of adolescent and young adult underrepresentation in clinical trials and offer evidence that such adiscrepancy may partially explain outcome differences.In addition, these chapters present information about biologic differences between specific cancer subtypes most common in younger children and those exhibited by the same cancers in adolescents and young adults, and offer plausible explanations for outcome differences as well as potential treatment strategies.
Cancer Gene Therapy
the authors comprehensively review the anticancer genes and gene delivery methods currently available for cancer gene therapy, including the transfer of genetic material into the cancer cells, stimulation of the immune system to recognize and eliminate cancer cells, and the targeting of the nonmalignant stromal cells that support their growth. They also thoroughly examine the advantages and limitations of the different therapies and detail strategies to overcome obstacles to their clinical implementation
Cancer Clinical Trials : Proactive Strategies
The ever-changing regulations for clinical trials and the ethical dilemma of treating cancer patients as subjects have made it ever so difficult for the principal investigators to conduct clinical research, especially when they are often ill-informed of the complex nature of the regulations and over-worked. Therefore, cancer clinical trials are at a critical junction. The objective of this book is to bring the issues of cancer clinical trials into focus so that proactive strategies may be developed to make such trials more user-friendly. Ultimately, the cancer patients will be benefited.
Cancer Chemoprevention ; Vol.2 : Strategies for Cancer Chemoprevention
In Cancer Chemoprevention, Volume 2: Strategies for Cancer Chemoprevention, leading chemopreventives investigators comprehensively describe the exciting methodologies that are accelerating progress in the chemoprevention field and review the state of clinical development of preventive agents in the major human cancer target organs. The authors provide sound guidelines for cancer chemopreventive drug development, detailing general strategies and methods for drug discovery, preclinical efficacy, characterization of precancers, safety evaluation of clinical cohorts, and clinical trial design.
Cancer and Pregnancy
This book is written by experts with clinical expertise on diagnosis, treatment, and follow-up of women with cancer during pregnancy. It provides a comprehensive review of data and an overview of psychological, ethical, and social aspects.
Biomarkers for alzheimer’s disease drug development
Helping to accelerate Alzheimer’s disease drug development. Addressing the latest advances in preclinical and clinical research, including new insights into the molecular mechanisms and emerging therapeutic strategies, the book continues by exploring digital biomarkers and advanced neuroimaging analysis which will transform how clinical trials in the Alzheimer’s disease field are performed.
Biologics in General Medicine
The idea for this book was born during the symposium on biologics organized by ZAFES (Center for Drug Research, Development and Safety at the University of Frankfurt am Main) in September 2005. Highly distinguished researchers special- ing in the field of biologics had gathered together to exchange information on this relatively new subject. Realizing that this symposium was one of the few sources of condensed information on biologics, it became obvious that we had to create a means of informing an interested wider circle of scientists and especially general c- nicians. Therefore, the editors of this book suggested to the researchers at the symposium andalsotoprominent scientists andcliniciansinvolvedinthe developmentand application of biologics as their major field of interest the idea of assembling this compendium. We received an overwhelmingly positive response – thankfully also from the publisher – most being more than willing to support this innovative project with highly relevant chapters on the latest state of the art.
Bioinformatics tools for pharmaceutical drug product development
Presents the latest information on bioinformatics tools, artificial intelligence, machine learning, computational methods, protein interactions, peptide-based drug design, and omics technologies. And include bioinformatics tools for the pharmaceutical sector and the healthcare sector. Bioinformatics brings a new era in research to accelerate drug target and vaccine design development, improving validation approaches as well as facilitating and identifying side effects and predicting drug resistance. As such, this will aid in more successful drug candidates from discovery to clinical trials to the market, and most importantly make it a more cost-effective process overall.
Aromatase Inhibitors
Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy.
Aromatase Inhibitors
Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy.
Application of Apoptosis to Cancer Treatment
This book is intended for workers in the field and clinicians as a useful guide of the state of affairs in this exciting field which may offer more effective possibilities for treatment of cancer patients.
Antiangiogenic Agents in Cancer Therapy
Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art of angiogenesis and therapy with a compendium of scientific findings and approaches to the study of angiogenesis in cancer. Leaders in the field present chapters on such topics as the environmental influences and the genetic and physiologic abnormalities that mediate angiogenesis and its role in the progression of malignant disease, working models of tumor angiogenesis, and the role of angiogenesis inhibition in the therapy of malignant disease in humans. Comprehensive and cutting-edge, Antiangiogenic Agents in Cancer Therapy, Second Edition is an ideal, valuable guide to the most recent advances in the field, and a collection that will be useful for many years to come.
Analyzing T cell responses : How to analyze cellular immune responses against tumor associated antigens
Active specific immunotherapy is a promising but investigational modality in the management of cancer patients. Currently, several different cancer vaccine formulations such as peptides, proteins, antigen-pulsed dendritic cells, whole tumor cells, etc. in combination with various adjuvants and carriers are being evaluated in clinical trials (1-3). To determine the optimal cancer
An introduction to clinical trials
An Introduction to clinical trials is a concise step-by-step guide to the principles and practices of clinical trials for those studying clinical trials or new to working on one. Clinical trials are critical to the progress of medicine and improving healthcare / as they evaluate whether new treatments and interventions work. They are also complex / multidisciplinary projects that integrate science / ethics / and legal requirements in the conduct of medical research.
